Full text is available at the source.
Abstract
Two potent AUTOTAC degraders, 6d and 11bg, selectively degrade EGFR and VEGFR2.
- AUTOTAC degraders target receptor tyrosine kinases (RTKs), which are important in cancer therapy.
- These degraders work through p62 recruitment and activate the autophagy-lysosome pathway without involving the ubiquitin-proteasome system.
- Both 6d and 11bg showed strong effects in reducing cancer cell growth, promoting cell death, and inhibiting migration in laboratory settings.
- 6d also demonstrated significant tumor-fighting effects in live models, with good tolerability observed.
Simplified